Diagnostic performance of bone scintigraphy and 11C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer

被引:15
|
作者
Garcia, J. R. [1 ]
Moreno, C. [1 ]
Valls, E. [1 ]
Cozar, P. [1 ]
Bassa, P. [1 ]
Soler, M. [1 ]
Alvarez-Moro, F. J. [1 ]
Moragas, M. [1 ]
Riera, E. [1 ]
机构
[1] Unidad PET CETIR ERESA, Barcelona, Spain
来源
REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR | 2015年 / 34卷 / 03期
关键词
Bone scintigraphy; C-11-Choline PET/CT; Bone metastases; Biochemical recurrence; Prostate cancer; POSITRON-EMISSION-TOMOGRAPHY; CELL LUNG-CANCER; F-18-FLUORIDE PET; F-18-FDG PET/CT; DISEASE; SPECT; ONCOLOGY; RELAPSE; CT;
D O I
10.1016/j.remn.2014.08.001
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Aim: To compare bone scan (BS) with C-11-Choline PET/CT for the detection of bone metastases in patients with biochemical recurrence of prostate cancer (PC). Material and Methods: A total of 169 patients with biochemical recurrence of PC(PSA:2.4-58 ng/ml) who were referred for both exams (0-15 days-in-between) were included. Lesion-detection-rate per patients and lesions were analyzed for both BS and C-11-Choline PET/CT. Metastasis diagnosis was reached by: biopsy, CT/F-18-Fluoride PET/MRI confirmation, or evidence of progression in subsequent imaging procedures. Results: A total of 91 lesions were found to be active in BS and/or C-11-choline PET/CT (40 patients), with 78 of which were metastatic. BS detected 38 blastic, 2 lytic and 10 non-CT-evident lesions. C-11-Choline PET/CT detected 41 blastic, 4 lytic and 29 non-CT-evident lesions. BS and C-11-Choline PET/CT sensitivities were 65.4% and 96.1%; specificities ere 38.5 and 92.3% (chi(2) 8.27, p < 0.04). Both imaging techniques were negative in 118 patients. Tracer avid lesions were found in 51 patients: with 30/51 being BS and C-11-Choline PET/CT concordant; in 21/51 patients had discordant lesions (kappa 0.712, p = 0.00). Lesions were absolutely discordant in 10/19 patients,: 5 FN BS, 2 FP BS (degenerative changes: dysplasia), 1 FN C-11-Choline PET/CT (blastic), 1 FP C-11-Choline PET/CT (degenerative), 1 out of field-of-view lesion with C-11-Choline PET/CT (tibia alone). C-11-Choline PET/CT showed extraosseous involvement in 26/51 patients with bone metastases: 9 local recurrences, 5 infra-diaphragmatic-lymph-nodes, 2 supra-diaphragmatic, 5 local and infra-diaphragmatic, 4 infra- and supra-diaphragmatic, 1 supra-diaphragmatic and lung metastases. Conclusion: C-11-Choline PET/CT yielded better sensitivity and specificity than BS for the detection of bone involvement in patients with biochemical recurrence of PC and allowed extraosseous restaging, with an impact in the clinical management of these patients. (C) 2014 Elsevier Espana, S.L.U. and SEMNIM. All rights reserved.
引用
收藏
页码:155 / 161
页数:7
相关论文
共 50 条
  • [31] Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer
    Scher, Bernhard
    Seitz, Michael
    Albinger, Wolfram
    Tiling, Reinhold
    Scherr, Michael
    Becker, Hans-Christoph
    Souvatzogluou, Michael
    Gildehaus, Franz-Josef
    Wester, Hans-Juergen
    Dresel, Stefan
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (01) : 45 - 53
  • [32] PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data
    Stefano Fanti
    Silvia Minozzi
    Paolo Castellucci
    Sara Balduzzi
    Ken Herrmann
    Bernd Joachim Krause
    Wim Oyen
    Arturo Chiti
    European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 55 - 69
  • [33] 11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer
    Mapelli, Paola
    Incerti, Elena
    Ceci, Francesco
    Castellucci, Paolo
    Fanti, Stefano
    Picchio, Maria
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 : 43S - 48S
  • [34] 11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT
    Francesco Ceci
    Paolo Castellucci
    Tiziano Graziani
    Riccardo Schiavina
    Eugenio Brunocilla
    Renzo Mazzarotto
    Maria Ntreta
    Filippo Lodi
    Giuseppe Martorana
    Stefano Fanti
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 878 - 886
  • [35] Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?
    Nicolas de Leiris
    Julien Leenhardt
    Bastien Boussat
    Christopher Montemagno
    Alexandre Seiller
    Olivier Phan Sy
    Julie Roux
    Mathieu Laramas
    Camille Verry
    Carole Iriart
    Gaelle Fiard
    Jean-Alexandre Long
    Jean-Luc Descotes
    Jean-Philippe Vuillez
    Laurent Riou
    Loïc Djaileb
    Cancer Imaging, 20
  • [36] Comparison of 18F-FDG-PET/CT with 99mTc-MDP bone scintigraphy for the detection of bone metastases in cancer patients
    Ozulker, Tamer
    Kucukoz, Aysun
    Ozulker, Filiz
    Ozpacaci, Tevfik
    NUCLEAR MEDICINE COMMUNICATIONS, 2010, 31 (06) : 597 - 603
  • [37] 11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT
    Ceci, Francesco
    Castellucci, Paolo
    Graziani, Tiziano
    Schiavina, Riccardo
    Brunocilla, Eugenio
    Mazzarotto, Renzo
    Ntreta, Maria
    Lodi, Filippo
    Martorana, Giuseppe
    Fanti, Stefano
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (05) : 878 - 886
  • [38] Diagnostic performance of choline PET/CT for the detection of bone metastasis in prostate cancer: A systematic review and meta-analysis
    Guo, Yu
    Wang, Ling
    Hu, Junjie
    Feng, Dehong
    Xu, Lijuan
    PLOS ONE, 2018, 13 (09):
  • [39] 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients
    Brogsitter, Claudia
    Zoephel, Klaus
    Kotzerke, Joerg
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S18 - S27
  • [40] Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer
    von Eyben, Finn E.
    Kairemo, Kalevi
    NUCLEAR MEDICINE COMMUNICATIONS, 2014, 35 (03) : 221 - 230